The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Boutry, Celine | - |
dc.contributor.author | Hastie, Andrew | - |
dc.contributor.author | Diez-Domingo, Javier | - |
dc.contributor.author | Tinoco, Juan Carlos | - |
dc.contributor.author | Yu, Chong-Jen | - |
dc.contributor.author | Andrews, Charles | - |
dc.contributor.author | Beytout, Jean | - |
dc.contributor.author | Caso, Covadonga | - |
dc.contributor.author | Cheng, Huey-Shinn | - |
dc.contributor.author | Cheong, Hee Jin | - |
dc.contributor.author | Choo, Eun Ju | - |
dc.contributor.author | Curiac, Dan | - |
dc.contributor.author | Di Paolo, Emmanuel | - |
dc.contributor.author | Dionne, Marc | - |
dc.contributor.author | Eckermann, Tamara | - |
dc.contributor.author | Esen, Meral | - |
dc.contributor.author | Ferguson, Murdo | - |
dc.contributor.author | Ghesquiere, Wayne | - |
dc.contributor.author | Hwang, Shinn-Jang | - |
dc.contributor.author | Avelino-Silva, Thiago Junqueira | - |
dc.contributor.author | Kosina, Pavel | - |
dc.contributor.author | Liu, Chiu-Shong | - |
dc.contributor.author | Markkula, Jukka | - |
dc.contributor.author | Moeckesch, Beate | - |
dc.contributor.author | de Oliveira, Claudia Murta | - |
dc.contributor.author | Park, Dae Won | - |
dc.contributor.author | Pauksens, Karlis | - |
dc.contributor.author | Pirrotta, Paola | - |
dc.contributor.author | Plassmann, Georg | - |
dc.contributor.author | Pretswell, Carol | - |
dc.contributor.author | Rombo, Lars | - |
dc.contributor.author | Salaun, Bruno | - |
dc.contributor.author | Berglund, Johan Sanmartin | - |
dc.contributor.author | Schenkenberger, Isabelle | - |
dc.contributor.author | Schwarz, Tino | - |
dc.contributor.author | Shi, Meng | - |
dc.contributor.author | Ukkonen, Benita | - |
dc.contributor.author | Zahaf, Toufik | - |
dc.contributor.author | Zerbini, Cristiano | - |
dc.contributor.author | Schuind, Anne | - |
dc.contributor.author | Cunningham, Anthony L. | - |
dc.date.accessioned | 2022-02-28T03:41:39Z | - |
dc.date.available | 2022-02-28T03:41:39Z | - |
dc.date.created | 2022-02-28 | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 1058-4838 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/137207 | - |
dc.description.abstract | Efficacy against herpes zoster and immune responses to the adjuvanted recombinant zoster vaccine plateaued at high levels between 5.1 and 7.1 years (mean) post-vaccination, suggesting that its clinical benefit in older adults is sustained for at least 7 years post-vaccination. Background This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age >= 50 years in 2 pivotal efficacy trials (ZOE-50 and ZOE-70). The present interim analysis was performed after >= 2 additional years of follow-up (between 5.1 and 7.1 years [mean] post-vaccination) and includes partial data for year (Y) 8 post-vaccination. Methods Annual assessments were performed for efficacy against herpes zoster (HZ) from Y6 post-vaccination and for anti-gE antibody concentrations and gE-specific CD4[2+] T-cell (expressing >= 2 of 4 assessed activation markers) frequencies from Y5 post-vaccination. Results Of 7413 participants enrolled for the long-term efficacy assessment, 7277 (mean age at vaccination, 67.2 years), 813, and 108 were included in the cohorts evaluating efficacy, humoral immune responses, and cell-mediated immune responses, respectively. Efficacy of RZV against HZ through this interim analysis was 84.0% (95% confidence interval [CI], 75.9-89.8) from the start of this follow-up study and 90.9% (95% CI, 88.2-93.2) from vaccination in ZOE-50/70. Annual vaccine efficacy estimates were >84% for each year since vaccination and remained stable through this interim analysis. Anti-gE antibody geometric mean concentrations and median frequencies of gE-specific CD4[2+] T cells reached a plateau at approximately 6-fold above pre-vaccination levels. Conclusions Efficacy against HZ and immune responses to RZV remained high, suggesting that the clinical benefit of RZV in older adults is sustained for at least 7 years post-vaccination. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS INC | - |
dc.subject | SUBUNIT VACCINE | - |
dc.subject | EPIDEMIOLOGY | - |
dc.subject | EFFICACY | - |
dc.title | The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Dae Won | - |
dc.identifier.doi | 10.1093/cid/ciab629 | - |
dc.identifier.scopusid | 2-s2.0-85116820049 | - |
dc.identifier.wosid | 000756453800001 | - |
dc.identifier.bibliographicCitation | CLINICAL INFECTIOUS DISEASES, v.74, no.8, pp.1459 - 1467 | - |
dc.relation.isPartOf | CLINICAL INFECTIOUS DISEASES | - |
dc.citation.title | CLINICAL INFECTIOUS DISEASES | - |
dc.citation.volume | 74 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1459 | - |
dc.citation.endPage | 1467 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.subject.keywordPlus | SUBUNIT VACCINE | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordAuthor | adjuvanted recombinant zoster vaccine | - |
dc.subject.keywordAuthor | long-term efficacy | - |
dc.subject.keywordAuthor | immune response persistence | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.